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Voltage-gated sodium (NaV) channels control the
upstroke of the action potentials in excitable cells.
Multiple studies have shown distinct roles of NaV
channel subtypes in human physiology and dis-
eases, but subtype-specific therapeutics are lack-
ing and the current efforts have been limited to
small molecules. Here, we present a monoclonal
antibody that targets the voltage-sensor paddle of
NaV1.7, the subtype critical for pain sensation.
This antibody not only inhibits NaV1.7 with high
selectivity, but also effectively suppresses inflam-
matory and neuropathic pain in mice. Interestingly,
the antibody inhibits acute and chronic itch despite
well-documented differences in pain and itch mod-
ulation. Using this antibody, we discovered that
NaV1.7 plays a key role in spinal cord nociceptive
and pruriceptive synaptic transmission. Our studies
reveal that NaV1.7 is a target for itch management,
and the antibody has therapeutic potential for sup-
pressing pain and itch. Our antibody strategy may
have broad applications for voltage-gated cation
channels.
INTRODUCTION
Voltage-gated sodium (NaV) channels are responsible for the
action potential initiation and propagation in excitable cells.
Humans possess nine highly homologous NaV channel sub-
types (NaV1.1–NaV1.9), and each subtype plays a distinct role
in various physiological processes and diseases such as
cardiac arrhythmia, epilepsy, ataxia, periodic paralysis, and
pain disorder (Cox et al., 2006; Escayg and Goldin, 2010;
Jurkat-Rott et al., 2010; Zimmer and Surber, 2008). In par-
ticular, recent human genetic studies have demonstrated a
critical role of NaV1.7 in pain sensation. Loss-of-function muta-
tions in SCN9A (the gene that codes for NaV1.7) in humans
lead to congenital inability to sense pain and anosmia without
affecting other sensations such as touch and temperature(Cox et al., 2006; Weiss et al., 2011), whereas gain-of-function
mutations lead to episodic pain such as primary erythrome-
lalgia and paroxysmal extreme pain disorder (Drenth et al.,
2001; Fertleman et al., 2006). Therefore, subtype-specific
NaV1.7 inhibitors could be novel analgesics for a broad range
of pain conditions.
Despite the importance of subtype selectivity, current NaV
channel-targeting drugs are poorly selective among the sub-
types, which may underlie their unwanted side effects (England
and de Groot, 2009; Nardi et al., 2012). To remove devastating
off-target effects (i.e., cardiac toxicity) and improve clinical effi-
cacy, it is urgent to develop subtype-specific therapeutics
against NaV channels (Bolognesi et al., 1997; Echt et al., 1991;
England and de Groot, 2009). Because of high sequence similar-
ity among the different NaV channel subtypes, the search for
subtype-specific NaV channel modulators has been slow despite
recent success (McCormack et al., 2013; Yang et al., 2013) and
has been largely limited to small-molecule screening (England
and de Groot, 2009; Nardi et al., 2012).
Subtype-specific NaV modulators can be powerful pharmaco-
logical tools to study unknown physiological roles of each NaV
subtype, which can complement genetic knockout studies. For
example, although the role of NaV1.7 in dorsal root ganglion
(DRG) has been extensively studied, its involvement in nocicep-
tive synaptic transmission is not clear. Furthermore, a NaV1.7-
specific modulator can address the role of NaV1.7 in other
sensory functions such as itch sensation. Although pruriceptive
neurons are a subset of nociceptive C fiber neurons in DRG,
recent progress indicates that there are separate labeled lines
for itch and pain in the spinal cord (Akiyama and Carstens,
2013; Han et al., 2013; Mishra and Hoon, 2013; Sun and Chen,
2007). Pain is known to suppress itch via an inhibitory circuit in
the spinal cord under normal physiological conditions, and this
suppression might be disrupted in pathological conditions (Liu
and Ji, 2013; Ma, 2010; Ross et al., 2010). The unique role
of NaV1.7 in acute- and chronic-itch conditions has not been
studied.
The pore-forming a subunit of NaV channels is composed of a
single polypeptide with four repeat domains (DI-DIV). Each
repeat contains six transmembrane helical segments (S1–S6).
The first four segments (S1–S4) comprise the voltage-sensor
domain (VSD), and the last two segments (S5–S6), whenCell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc. 1393
Figure 1. Locations of the Epitopes and Their Sequences among the
NaV Subtypes
(A) The chosen epitopes are mapped on the crystal structure of a bacterial NaV
channel (Payandeh et al., 2011). One of the four repeats, composed of six
transmembrane helices (S1–S6; 1–6), is colored green. The loops between
S3-S4 and between S1-S2 are colored red and blue, respectively.
(B and C) Sequence alignments corresponding to the S3-S4 (B) and S1-S2 (C)
loops of hNaV subtypes. The regions chosen for raising antibodies are colored
red and blue, respectively.assembled in a tetrameric configuration, form the pore domain.
Within the VSD, S4 contains the gating charge arginine residues
that sense membrane potential changes and, together with the
C-terminal half of S3 (S3b), form a helix-turn (loop)-helix known
as the voltage-sensor paddle (Jiang et al., 2003a) (Figure 1A).
Structural and biophysical studies have shown that the
voltage-sensor paddle moves in response to changes in mem-
brane potential, and thismotion is coupled to pore opening, clos-
ing, and inactivation (termed gating) (Armstrong and Bezanilla,
1974; Cha et al., 1999; Jiang et al., 2003b). Because the motion
of the voltage-sensor paddle is key to channel gating, locking it in
place via protein-protein interactions modulates channel gating.
In fact, this strategy is employed by a class of natural peptide
toxins called gating-modifier toxins (Ceste`le et al., 1998; Swartz
and MacKinnon, 1997a).
We hypothesized that the voltage-sensor paddle region is an
ideal target to develop subtype-selective NaV channel modula-
tors because of its allosteric control of channel gating and its
sequence diversity among the NaV subtypes (Figure 1B). More-
over, we reasoned that a monoclonal antibody would be well
suited to attack voltage-sensor paddles because it can form
highly specific interactions with its target, and importantly anti-
bodies can be utilized therapeutically due to their low toxicity
and long half-life (Eijkelkamp et al., 2012).
The aims of our studies are to test (1) whether voltage-sensor
paddle targeting antibody can be developed for subtype-
specific modulation of NaV1.7, (2) whether the antibody has
therapeutic efficacy in vivo, and (3) whether the antibody can
be used to uncover the unknown role of NaV1.7 in pain- and
itch-mediated synaptic transmission in the spinal cord.1394 Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc.RESULTS
Voltage-Sensor-Paddle-Targeting Antibody Inhibits the
Function of NaV1.7 in HEK Cells
To direct antibody to target voltage-sensor paddle, instead of
using the intact channel as antigen for raising antibodies, we
chose a peptide that corresponds to the tip (loop) of the
voltage-sensor paddle (the S3-S4 loop) from DII on the basis of
the crystal structure of the bacterial NaV channel NaVAb (Payan-
deh et al., 2011) (Figure 1B). We also chose a peptide that corre-
sponds to the S1-S2 loop as a negative control because the
S1-S2 loop does not move upon membrane potential change,
and thus antibody binding would not likely affect channel gating
significantly (Figure 1C). We successfully raised one antibody for
each region: SVmab1 (sodium channel voltage sensor mono-
clonal antibody 1) for the S3-S4 loop and CTmab (control mono-
clonal antibody) for the S1-S2 loop. Both antibodies belong
to the same subtype and show positive ELISA responses against
the recombinant DII voltage sensor domain, confirming that they
recognize their target loops in the intact VSD (Figure S1 available
online).
To test the effects of these antibodies on NaV1.7 channels, we
performed patch-clamp recordings on hNaV1.7 channels ex-
pressed transiently in HEK293 cells using the whole-cell voltage
clamp configuration. When 1 mM of CTmab was added to the
extracellular side, we did not observe any significant changes
on peak sodium currents (Figures 2A–2C). However, addition
of 100 nM of SVmab1 resulted in significant reduction of the
peak sodium currents (Figures 2D–2F).
To test whether the observed effects of SVmab1 arise from
specific interactions with the tip (loop) of the voltage-sensor
paddle and not from fortuitous interactions between SVmab1
and NaV1.7, we performed recordings of NaV1.7 in the presence
of both SVmab1 and the peptide that was used as antigen to
raise SVmab1 (Figures 2G–2I). The presence of 1 mM peptide
essentially blocks the inhibitory effects of 100 nM SVmab1 on
NaV1.7, confirming that the specific interactions between the
voltage-sensor paddle and SVmab1 lead to NaV1.7 inhibition.
SVmab1 Inhibits NaV1.7 by Stabilizing a Closed State
and in a State-Dependent Manner in HEK293 Cells
Comparison of conductance-voltage relationships for control
and SVmab1-modified currents shows a depolarized shift
(20 mV) upon addition of 100 nM of SVmab1 (Figure 3A). In
contrast, comparison of steady-state inactivation curves shows
no changes in half-inactivation voltage upon addition of SVmab1
(Figure 3B).
Current drugs targeting NaV channels have only gained
modest selectivity by their state (use)-dependent inhibition prop-
erties (England and de Groot, 2009). To test whether the effect of
SVmab1 on NaV1.7 is state dependent, currents were elicited
during 30 ms depolarizing pulses to 10 mV from a holding
potential of 120 mV at three different frequencies (0.1, 2, and
10 Hz) with and without 100 nM SVmab1 (Figure 3C). The rates
of channel inhibition by 100 nM SVmab1 increased following
higher frequency. Strikingly, concentration-response relation-
ships show that both potency (IC50 from 106 nM to 16.7 nM)
and efficacy (degree of maximum inhibition from 84% to 99%)
Figure 2. SVmab1 Inhibits hNaV1.7 through
Specific Interactions between the Voltage-
Sensor Paddle and SVmab1
Representative current traces from HEK293 cells
expressing hNaV1.7 in the absence (A) or presence
(B) of 1 mM CTmab and in the absence (D) or
presence (E) of 100 nM SVmab1. Current-voltage
relationships in the absence (B) or presence (C) of
1 mM CTmab (C) and 100 nM SVmab1 (F) were
generated using 30ms voltage steps between80
and +60 mV with 10 mV increments from a holding
potential of120 mV. Data are shown as means ±
SEM; n = 8–11 per group. Representative traces
from HEK293 cells expressing hNaV1.7 channels
(G), in the presence of SVmab1 (100 nM) and the
peptide (1 mM) (H), and in the presence of SVmab1
(100 nM) only after washout SVmab1 and the
peptide (I).are enhanced upon increase in frequency from 0.1 to 10 Hz
(Figure 3D).
The reduction of current amplitudes and the depolarized shift
in current-voltage relationships of NaV1.7 by SVmab1 suggest
that SVmab1 inhibits NaV1.7 by stabilizing a closed state, similar
to the effects of Hanatoxin on KV 2.1 or ProTx-II on NaV channels
(Schmalhofer et al., 2008; Swartz and MacKinnon, 1997a). How-
ever, unlike Hanatoxin or ProTx-II, SVmab1 exhibits state-
dependent inhibition of NaV1.7, suggesting that SVmab1 utilizes
a different mechanism.
SVmab1 Inhibits NaV1.7 in a Subtype-Specific Manner in
HEK293 Cells
To test subtype specificity of SVmab1, we performed recordings
on different NaV subtypes (NaV1.1–NaV1.8) expressed transiently
inHEK293cells. Exposureof cells to 10mMofSVmab1showedno
appreciable inhibition of majority of NaV subtypes (except for par-
tial effects on NaV1.6) when current-voltage curves were plotted
(Figure 4A). The partial inhibition of SVmab1 on NaV1.6 at high
concentrations was expected, given the sequence similarity be-
tween NaV1.6 and NaV1.7 at the S3-S4 loop (Figures 1B and
S2). It is unlikely that SVmab1 would have significant effects on
NaV1.9, given the sequence difference in the S3-S4 loop of
NaV1.7 and NaV1.9 (Figure 1B). Dose-response curve shows
that SVmab1 is highly specific for NaV1.7 in terms of potency
and efficacy (Figure 4B). Although SVmab1 affects NaV1.6
with 200-fold less potency and 2-fold less efficacy (44%
maximum inhibition), it has almost no effects on other NaV sub-
types, with very low efficacy (maximum inhibition of 10%–20%
at 30 mM) and potency (several-hundred-fold lower). If potency
and efficacy are considered together, SVmab1 is at least 400- to
1,500-fold more selective for NaV1.7 than other NaV subtypesCell 157, 1393–14(Table 1). To the best of our knowledge,
SVmab1 blocks NaV1.7 with the highest
specificity that has ever been reported.
SVmab1Reduces Inflammatory and
Neuropathic Pain in Mice
Armed with a selective antibody that can
inhibit hNaV1.7 in vitro, we next tested thein vivo effects of SVmab1 on pain sensitivity using mouse
models. Because the sequence for the region chosen to raise
SVmab1 is identical between human and mouse, we expected
that this antibody should work in mice by acting on mNaV1.7.
We first tested whether SVmab1 could attenuate formalin-
induced inflammatory pain following spinal intrathecal (i.t.) route
via lumbar puncture. Intraplantar injection of diluted formalin
(5%) elicits typical two-phase inflammatory pain for 45 min (Fig-
ure 5A). Notably, i.t. SVmab1 (1 and 10 mg, i.e., 0.006 and
0.06 nmol) produces substantial inhibition of the second-phase
pain and moderate inhibition of the first-phase pain (Figures 5A
and 5B). In contrast, the motor function in the rota-rod test
was not affected by i.t. SVmab1 at a high dose (50 mg, Figure 5C).
Systemic injection of SVmab1 via i.v. route (10 and 50 mg/kg,
i.e., 0.06 and 0.3 mmol/kg) also dose dependently inhibited
formalin-induced pain in both phases (Figures 5D and 5E). The
apparent higher efficacy of SVmab1 via i.t. route is possibly a
result of high local concentrations of SVmab1 via i.t. route due
to small i.t. volume. As expected, intraplantar injection of
SVmab1 (50 mg, i.pl.) also effectively reduced the first- and
second-phase pain (Figure S3). Notably, the analgesic doses
of SVmab1 (0.06 nmol, i.t. and 0.3 mmol/kg, i.v.) are lower than
that of morphine (0.1–1 nmol, i.t. and 0.3–3 mmol/kg, i.v.) (Xu
et al., 2010), a widely used analgesic. Furthermore, formalin-
induced paw edema was suppressed by systemic SVmab1 (Fig-
ure 5F), indicating that NaV1.7 also contributes to neurogenic
inflammation.
Because neuropathic pain is generally more resistant to anal-
gesics, we further tested the efficacy of SVmab1 in neuropathic
pain, induced by chronic constriction injury (CCI) of the sciatic
nerve. Mechanical allodynia (decrease in paw withdrawal
threshold), a cardinal feature of neuropathic pain, is evident04, June 5, 2014 ª2014 Elsevier Inc. 1395
Figure 3. SVmab1 Inhibits NaV1.7 by Stabilizing aClosed State and in
a State-Dependent Manner in HEK293 Cells
(A) Voltage dependence of steady-state activation in the absence (B) or
presence (C) of 100 nM SVmab1. Activation curves were generated using a
30 ms test pulse in 5 mV increments from 90 to +10 mV from a holding
potential of 120 mV. Values from individual cells were normalized to the
maximum conductance value (G0) in the absence of SVmab1. Normalized
curves were fit using the Boltzmann equation. The solid squares (-) show the
same SVmab1-modified activation curve as the solid circles (C) but scaled to
the curve in the absence of SVmab1 (B). The half-activation voltage (Vmid) in
the presence of SVmab1 (C) was 24.0 ± 0.2 mV compared with 43.9 ±
0.2 mV in the absence of SVmab1 (B). n = 9–12 per group.
(B) Steady-state inactivation curves in the absence (B) or presence (C) of
100 nM SVmab1 were obtained using 5 mV increments from 110 mV to
30 mV for 500 ms followed by a test pulse to 10 mV for 30 ms. Values from
individual cells were normalized to the maximum current value (I0) in the
absence of SVmab1. The solid squares (-) show the same SVmab1-modified
steady-state inactivation curve as the solid circles (C) but scaled to the curve
in the absence of SVmab1 (B). The half-inactivation voltagewas unaffected by
SVmab1 (79.3 ± 0.3mV in the absence of SVmab1 [B] and78.6 ± 0.2mV in
the presence of SVmab1 [C]). n = 10–12 per group.
(C) State (use)-dependent inhibition of hNaV1.7 by SVmab1. Plot of normalized
current amplitudes during 30ms depolarizing pulses to10mV applied from a
holding potential of 120 mV at 0.1 (6), 2 (B), and 10 (,) Hz in the presence
of 100 nM SVmab1. n = 8–11 per group.
(D) Concentration-response curves of SVmab1 inhibition of hNaV1.7 currents
at different frequencies (0.1, 2, and 10 Hz). IC50 and maximum inhibition
values are 106.7 ± 18.0 nM and 83.7 ± 5.6% for 0.1 Hz, 30.7 ± 1.9 nM and
86.0 ± 2.3% for 2 Hz, and 16.7 ± 1.6 nM and 98.6 ± 4.1 for 10 Hz. n = 7–10 per
group.
All of the data are shown as means ± SEM.3 days after CCI surgery (Figure 5G). SVmab1 (50 mgz0.3 nmol,
i.t.) transiently reversed CCI-induced allodynia for several hours
(Figure 5G). Furthermore, systemic injection of SVmab1 via i.v.
route (10 and 50 mg/kg) is also effective in reversing established
mechanical allodynia, and the analgesic effect lasted 24 hr after
the injection (Figure 5H). Notably, multiple injections of SVmab1
showed no signs of antinociceptive tolerance (Figure 5H). Thus,
targeting NaV1.7 with SVmab1 could alleviate both inflammatory
and neuropathic pain via both central mechanisms (intrathecal
route) and peripheral mechanisms (systemic route).1396 Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc.SVmab1 Regulates Sodium Currents and Action
Potentials in Native DRG Neurons
Because NaV1.7 is heavily expressed by small-sized nociceptive
DRG neurons (Minett et al., 2012), we examined whether
SVmab1 would also modulate NaV1.7 in native neurons by
recording transient sodium currents (INaT) in dissociated small-
sized DRG neurons. Current-voltage relationship showed that
SVmab1 (7, 70, and 300 nM) dose dependently inhibited peak
INaT, but CTmab (300 nM) had no effects (Figure 6A). Further
analysis revealed that SVmab1 at 300 nM suppressed INaT by
76% (Figures 6B and 6C). By contrast, INaT in large-sized
DRG neurons were only inhibited by TTX (1 mM), but not SVmab1
(300 nM), suggesting a specific effect of SVmab1 on small-sized
neurons (Figure 6D). As expected, SVmab1 also suppressed
action potentials in dissociated small-sized DRG neurons fol-
lowing current injection (Figures 6E, 6F, and S4A).
Next, we tested the effects of SVmab1 on NaV1.7-mediated
persistent sodium currents (INaP) in small-sized DRG neurons.
SVmab1, but not CTmab (300 nM), largely inhibited INaP
(64%, Figure S4B) in dissociated small-sized DRG neurons.
We also recorded INaP in an ex vivo condition using whole-
mount DRG. In this preparation, INaP in small-sized neurons
were partially (37%) inhibited by SVmab1 (300 nM, Fig-
ures 6G and 6H). The discrepancy in INaP inhibition in dissoci-
ated DRG neurons (64%) and whole-mount DRG neurons
(37%) likely reflects limited antibody access in whole-mount
recordings. Interestingly, nerve injury by CCI increased INaP,
and SVmab1 (300 nM) produced a greater inhibition of the cur-
rent (50%) in this neuropathic pain condition, consistent with
its state-dependent inhibition properties shown in HEK293
cells (Figure 6H). SVmab1 (300 nM) also inhibited action
potentials and INaT in whole-mount DRG neurons (Figures
S4C and S4D).
SVmab1 Suppresses Nociceptive Synaptic
Transmission in Spinal Cord Dorsal Horn
To determine the synaptic mechanisms by which spinal admin-
istration of SVmab1 reduces pain, we conducted patch-clamp
recordings in spinal cord slices to measure spontaneous excit-
atory postsynaptic currents (sEPSCs) in lamina IIo interneurons
that form a pain circuit with C fibers as input and lamina I
projection neurons as output (Todd, 2010). Perfusion of
spinal cord slices with SVmab1 (7, 70, and 300 nM) dose
dependently reduced sEPSC frequency (Figures 6I and 6J)
without affecting the amplitude of sEPSCs (data not shown).
At the dose of 300 nM, SVmab1 suppressed the frequency of
sEPSCs by 48%. In contrast, CTmab (300 nM) did not alter
sEPSCs frequency (Figures 6I and 6J). For comparison, TTX
(1 mM) reduces sEPSC frequency by 60%, which is signifi-
cantly higher than that of 300 nM SVmab1 (Figure 6J). SVmab
also delayed the conduction of action potentials in lamina IIo
neurons induced by dorsal root stimulation at C fiber intensity
(Figure S5).
We further tested the NaV1.7-mediated synaptic transmission
in neuropathic pain. Interestingly, sEPSC in lamina IIo neurons
was significantly increased in neuropathic pain after CCI (Figures
6K and 6L). SVmab1wasmore effective in suppressing sEPSC in
neuropathic pain, and no difference was found between the
Figure 4. SVmab1 Inhibits hNaV1.7 in a Sub-
type-Specific Manner in HEK293 Cells
(A) Current-voltage relationships of the seven
different NaV channel subtypes in the absence (B)
and presence (C) of 10 mM SVmab1. Voltage
steps were applied from 80 to +60 mV taken in
10 mV increments for 30 ms at a holding potential
of120 mV. Data are shown as means ± SEM; n =
6–9 per group.
(B) Concentration-response curves of the NaV
channel subtypes (IC50 = 30.9 ± 1.9 nM for NaV1.7,
6.3 ± 2.2 mM for NaV1.6, and > 5 mM for NaV1.1,
1.2, 1.3, 1.4, 1.5, and 1.8). Sodium currents were
elicited by stepping to 10 mV from a holding
potential of 120 mV for a duration of 30 ms at a
frequency of 2 Hz. Data are shown as means ±
SEM; n = 6–10 per group.TTX-treated (1 mM) and SVmab1-treated (300 nM) groups (Fig-
ures 6K and 6L). Thus, NaV1.7 plays a major role in spinal cord
nociceptive synaptic transmission, especially in neuropathic
pain condition.
SVmab1 Reduces Acute and Chronic Itch and Chronic
Itch-Potentiated Synaptic Transmission
To study the role of NaV1.7 in itch sensation, we first examined
the effects of SVmab1 on acute itch by observing the scratching
behaviors in mice following intradermal injection of histamine-
dependent pruritic agent (compound 48/80) and histamine-inde-
pendent pruritic agent (chloroquine, CQ) into the nape of the
neck. Spinal injection of SVmab1 (50 mg, i.t.) suppressed both
compound 48/80- and CQ-induced scratching (Figures 7A and
7B), indicating that NaV1.7 is required for eliciting both hista-
mine-dependent and -independent itch. Gastrin-releasing pep-
tide (GRP) binds GRP receptor (GRPR) in superficial dorsal
horn neurons to elicit itch (Sun and Chen, 2007). SVmab1
(50 mg, i.t.) substantially inhibited GRP-evoked (1 nmol, i.t.)
scratching (Figure 7C), indicating that NaV1.7 is involved in spinal
GRPR-mediated itch transmission.
To determine the role of NaV1.7 in chronic itch, we induced a
dry skin model by painting the back skin with acetone and
diethyether followed by water (AEW) for 5 days (Liu et al.,
2012). AEW-evoked spontaneous itch was suppressed by the
SVmab1 via either intrathecal (50 mg, Figure 7D) or i.v. route
(10 mg/kg, Figure 7E). We also generated the allergic contact
dermatitis (ACD) model of chronic itch by the hapten 2,4-dinitro-Cell 157, 1393–14fluorobenzene (DNFB). Treatment of the
back skin with DNFB induced progres-
sive scratching (Figure 7F), which was
reduced by both i.t. SVmab1 (50 mg) and
i.v. SVmab1 (50 mg/kg) (Figures 7G
and 7H).
Finally, we examined whether SVmab1
also modulated itch-related synaptic
transmission in lamina IIo neurons of
spinal cord slices. Notably, AEW treat-
ment increased sEPSC in lamina II neu-
rons, suggesting that chronic itch can
potentiate excitatory synaptic transmis-sion. SVmab1 (300 nM) also effectively suppressed sEPSC in
chronic itch (Figures 7I and 7J).
DISCUSSION
We have developed amonoclonal antibody that targets a NaV1.7
voltage-sensor paddle, which inhibits the function of NaV1.7
in vitro with high specificity and potency. Remarkably, the anti-
body exhibits significant analgesic effects in mouse models of
inflammatory and neuropathic pain without impairing motor
function. Furthermore, the antibody suppresses acute and
chronic itch in mouse models. Taking advantage of this selective
antibody, we also discovered previously unknown roles of
NaV1.7 in spinal cord nociceptive and pruriceptive synaptic
transmission.
Voltage-Sensor Paddle as a Target for the Development
of Subtype-Specific Modulators
Voltage-sensor-paddle-targeting antibody was first shown from
the structural studies of KvAP in complex with Fab fragments
(Jiang et al., 2003a). By targeting the voltage-sensor paddle,
we have developed a monoclonal antibody that inhibits the
function of NaV1.7 in a subtype-specific and state-dependent
manner. The current NaV channel drug-binding sites, localized
within the inner membrane leaflet region of the pore domain
(S6) of NaV channels, are highly conserved among the subtypes
(Cronin et al., 2003). Targeting voltage-sensor paddles within the
VSDs offers advantages over targeting pore domains because of04, June 5, 2014 ª2014 Elsevier Inc. 1397
Table 1. Selectivity of SVmab1 for Nav1.7
Maximum
Inhibition (%) IC50 (mM)
a
Selectivity
for NaV1.7
NaV1.1 20.7 ± 9.2 6.3 ± 4.4 861.5
NaV1.2 18.7 ± 9.9 9.0 ± 9.8 1362.3
NaV1.3 16.2 ± 7.6 8.7 ± 4.8 1520.1
NaV1.4 21.5 ± 9.4 7.9 ± 6.6 1040.1
NaV1.5 19.1 ± 7.5 5.6 ± 7.7 829.9
NaV1.6 44.2 ± 5.9 6.3 ± 2.2 403.5
NaV1.7 86.9 ± 2.9 0.0307 ± 0.0019 1
NaV1.8 22.1 ± 7.8 5.2 ± 6.9 666.1
Selectivity = (MaxNav1.7/MaxNav1.x) 3 (IC50Nav1.x/IC50Nav1.7).
aIC50 values were measured at 2 Hz and are shown as means ± SEM;
n = 6–10 per each subtype.their sequence diversity, their allosteric roles in channel conduc-
tion, and their pharmacological potential (Alabi et al., 2007;
Swartz and MacKinnon, 1997b). Despite the obvious advan-
tages, the voltage-sensor paddle has not been explored as
a target for subtype-specific modulators mainly because
voltage-sensor paddles change their accessibility with respect
to the membrane during voltage-dependent gating, making
them difficult to be captured and held in place by small mole-
cules. Furthermore, most peptide toxins targeting voltage-
sensor paddles gain much of their binding energy by membrane
partitioning so that the specific interactions between the toxins
and voltage-sensor paddles are not substantial, limiting the
capability to develop drugs with specificity (Lee andMacKinnon,
2004). Our antibody strategy has presented a solution to these
problems. By directly raising a monoclonal antibody that cap-
tures a voltage-sensor paddle of NaV1.7, we have achieved
subtype-specific modulation of NaV1.7.
Role of NaV1.7 in Modulating Spinal Cord Synaptic
Transmission in Pain and Itch
Our findings demonstrate a critical role of NaV1.7 in modu-
lating the spinal cord synaptic transmission in the context of
pain and itch. NaV1.7, expressed by nociceptive neurons in
DRG and the spinal cord central terminals of primary afferents
(Black et al., 2012), could control glutamate release from spinal
cord presynaptic terminals, which form synapses with lamina
IIo interneurons that we recorded (Figure S6). In turn, these
IIo neurons form a nociceptive circuitry with lamina I projection
neurons (Todd, 2010). Notably, excitatory synaptic transmis-
sion (sEPSC frequency) in these IIo neurons is greatly potenti-
ated in both chronic pain and itch conditions. Under the
normal conditions, NaV1.7 critically contributes to TTX-sensitive
sodium channel-mediated excitatory synaptic transmission. In
neuropathic pain, NaV1.7 plays a more important role in
excitatory synaptic transmission, as sEPSC suppression by
TTX was completely precluded by SVmab1. Thus, apart from
well-demonstrated peripheral mechanism of NaV1.7 in pain
initiation (Figures 6A–6H), our findings also demonstrate an
unrecognized central mechanism of NaV1.7 in modulating
excitatory synaptic transmission in the spinal cord pain circuitry
(Figure S6).1398 Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc.Increasing evidence suggests that pain and itch are mediated
by similar but distinct pathways in the spinal cord, and pain is
known to suppress itch via inhibitory neurons in physiological
conditions (Akiyama and Carstens, 2013; Liu and Ji, 2013; Ma,
2010; Ross et al., 2010). Importantly, excitatory interneurons in
the superficial dorsal horn are required for the full behavioral
expression of both pain and itch (Wang et al., 2013). Consis-
tently, our results showed that intrathecal SVmab1 not only in-
hibits pain and itch, but also suppresses the excitatory synaptic
transmission in these lamina IIo interneurons in the normal and
chronic pain/itch conditions. Intrathecal AMPA receptor antago-
nist was also shown to inhibit acute itch (Akiyama et al., 2013).
Although spinal cord glutamate transmission was implicated in
pain suppression of itch (Liu et al., 2010), our findings suggest
that part of the glutamate transmission underlying the expres-
sion of sEPSCs that we recorded in lamina IIo is required for
the transmission of both pain and itch (Figure S6). It was also
shown that glutamate is the major neurotransmitter in GRPR-
expressing neurons (Koga et al., 2011). Thus, SVmab1 may
block GRP-induced itch via suppressing glutamatergic neuro-
transmission that could be potentiated by GRP. Given the role
of NaV1.7 in itch sensation, it would be interesting to see whether
patients with CIP have reduced itch sensation, which was not
tested (Cox et al., 2006).
Therapeutic Potentials of an Ion-Channel-Targeting
Monoclonal Antibody
Antibody-based therapy is a rapidly growing field. Therapeutic
antibodies have been successfully used to treat cancer and
immune diseases by targeting receptors or secreted proteins
(Chan and Carter, 2010; Scott et al., 2012). Despite the fact
that many ion channels are proven drug targets, there is no anti-
body therapeutics against ion channels.
Antibodies have been generated and used for functional
studies of voltage-gated ion channels since the first monoclonal
antibody against NaV channels of rat skeletal muscle about
30 years ago (Casadei et al., 1984). Although many antibodies
have been developed to further ion channel research (Liao
et al., 2008; Xu et al., 2005), none has been shown to have in vivo
effects in animal models to the best of our knowledge (Eijkel-
kamp et al., 2012; Sun and Li, 2013). Our work demonstrates
the feasibility of therapeutic antibody development for treating
ion channel-related diseases.
It is noteworthy to compare the effects of SVmab1 with
ProTx-II, a peptide toxin that binds to a similar region of
NaV1.7 as SVmab1. ProTx-II inhibits the function of NaV1.7
with higher potency (IC50 of 0.5 nM) but lower selectivity
than SVmab1. Notably, ProTx-II does not have any analgesic ef-
fects in mice when systemically introduced and kills mice in
5 min when intrathecally introduced (Schmalhofer et al.,
2008). ProTx-II was effective only when the C fiber neurons
were desheathed, suggesting that ProTx-II cannot access
NaV1.7 channels in intact neurons. On the contrary, SVmab1
altered NaV1.7 channel function in intact lamina IIo and DRG
neurons as well as its in vivo effects in animal models without
impairing motor function. Thus, monoclonal antibodies can
confer many therapeutic advantages, including selectivity and
accessibility.
Figure 5. SVmab1 Reduces Inflammatory and Neuropathic Pain without Affecting Motor Coordination and Balance
(A and B) Intrathecal injection of SVmab1 reduces the formalin-induced inflammatory pain. (A) Time course of licking and flinching behavior following intraplantar
injection of 5% formalin. (B) Formalin-induced phase I (1–10 min) and phase II (10–45 min) responses. *p < 0.05, compared with the corresponding control
(CTmab).
(C) Falling latency (time on rota-rod) in the rota-rod test and the effects of SVmab1 and CTmab (50 mg, i.t.).
(D–F) Systemic injection of SVmab1 (10 and 50mg /kg, i.v.) also reduces the formalin-induced inflammatory pain and edema. (D) Time course of formalin-induced
pain. (E) Formalin-induced first- and second-phase responses. (F) Formalin-induced paw edema (volume of an affected hindpaw).
(G) Intrathecal (i.t.) injection of SVmab1 (50 mg) reduces the CCI-induced neuropathic pain (mechanical allodynia).
(H) Systemic injections of SVmab1 (10 and 50mg/kg, i.v.) dose dependently reduce the CCI-induced neuropathic pain (mechanical allodynia). Arrows indicate the
time at which antibodies were injected.
All of the data are shown as means ± SEM. BL, baseline. *p < 0.05, versus corresponding CTmab at the same dose (B, E, F, G, and H); #p < 0.05 versus baseline
(F). n = 5–6 mice per group.With the aids of recent advances in antibody engineering,
many pharmacological properties of ion-channel-targeting anti-
bodies including SVmab1, such as potency, efficacy, half-life,
and accessibility, can be improved (Beck et al., 2010). Further-
more, new technologies are available to enable antibodies to
pass across the blood-brain barrier (BBB), which is particularly
useful for antibodies targeting ion channels in CNS (Pardridge
and Boado, 2012).Conclusions
SVmab1 is effective in reducing pain and itch via both systemic
and intrathecal route, suggesting that NaV1.7 controls pain and
itch via both peripheral and central (spinal) mechanisms. Our
findings suggest that, to improve the therapeutic efficacy of
pain and itch suppression by NaV1.7-specific inhibitors, one
should consider targeting NaV1.7 through both peripheral and
central mechanisms.Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc. 1399
Figure 6. SVmab1 Suppresses Transient and Persistent Sodium Currents and Action Potentials in Small-Sized DRG Neurons and Noci-
ceptive Synaptic Transmission in Spinal Cord Slices
(A–D) SVmab1 suppresses transient sodium currents (INaT) in dissociated DRG neurons. (A) Current-voltage relationship of INaT and the effects of SVmab1 (7, 70,
and 300 nM) and CTmab (300 nM), n = 15–20 neurons per group. (B) Traces of INaT and the effects of SVmab1, CTmab (300 nM), and TTX (1 mM). (C) Percentage
inhibition of INaT by SVmab1 and TTX (1 mM). *p < 0.05 versus control (no treatment);
#p < 0.05 versus CTmab (300 nM); &p < 0.05, n = 15–20 neurons per group.
Note that TTX (1 mM) further inhibits INaT compared with SVmab1 (300 nM). (D) TTX (1 mM) but not SVmab1 (300 nM) inhibits INaT in large-sized DRG neurons.
n = 10 neurons per group.
(E and F) SVmab1 inhibits the action potential frequency in dissociated small-sized DRG neurons. (E) Traces of action potentials. (F) Action potential frequencies
following current injection (100 and 200 pA). *p < 0.05, n = 15–20 neurons per group.
(G and H) SVmab1 inhibits persistent sodium currents (INaP) in small-sized neurons of whole-mount DRGs from naive mice and mice with nerve injury (CCI).
(G) Traces of INaP before treatment (control) and after treatment with CTmab (300 nM) and SVmab1 (300 nM). (H) Amplitudes of INaP in DRG neurons, which are
increased after CCI. Note that SVmab1 (300 nM) produces a greater inhibition of INaP after CCI. *p < 0.05, n = 6–7 neurons per group.
(I and J) SVmab1 inhibits excitatory synaptic transmission in lamina IIo neurons of spinal cord slices of normal mice. (I) Traces of spontaneous EPSCs (sEPSCs).
(Bottom) Enlargements of traces (1, 2, 3) before and during the CTmab and SVmab1 treatment (300 nM). (J) Frequency of sEPSCs. *p < 0.05, versus baseline; #p <
0.05, versus CTmab (300 nM); &p < 0.05, n = 5–6 neurons per group.
(K and L) SVmab1 inhibits chronic pain-potentiated excitatory nociceptive synaptic transmission in lamina IIo neurons of spinal cord slices 4 days after CCI.
(K) Traces of sEPSCs. (Bottom) Enlargements of traces (1, 2, 3) before and during the CTmab and SVmab1 treatment (300 nM). (L) Frequency of sEPSCs.
*p < 0.05, versus no treatment baseline after CCI; #p < 0.05, versus CTmab (300 nM), n = 5 neurons per group. Note that SVmab1 is as effective as TTX at
suppressing synaptic transmission in chronic pain. n.s., no significance.
All of the data are shown as means ± SEM.Because voltage-sensor paddles from other voltage-gated ion
channels (e.g., Ca2+ or K+ channels) also share many features
(sequence diversity among subtypes, targets of peptide toxins,
allosteric control in gating) with NaV channels, our monoclonal
antibody strategy can be, at least in principle, applied to other
voltage-gated cation channels (e.g., Ca2+ or K+ channels) to
develop subtype-specific modulators.1400 Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc.EXPERIMENTAL PROCEDURES
Antibody Generation and Purification
Mouse monoclonal antibodies were generated by Abmart using peptides
with the following sequences: HHPMTEEFKN (CTmab) and VELFLADVEG
(SVmab1). Both antibodies are IgG1. After receiving hybridomas, multiple
rounds of limiting dilution cloning were performed to select a stable mono-
clonal cell population. Enzyme-linked immunosorbent assays (ELISA) using
Figure 7. SVmab1 Suppresses Acute and
Chronic Itch and Chronic Itch-Potentiated
Synaptic Transmission in Spinal Cord Slices
in Mice
(A–C) Intrathecal injection of SVmab1 reduces
acute itch induced by compound 48/80 (A, intra-
dermal), CQ (B, intradermal), and GRP (C, intra-
thecal). *p < 0.05, n = 5–8 mice per group.
(D and E) Intrathecal (50 mg, D) or i.v. (10 mg/kg, E)
injection of SVmab1 reduces dry-skin-induced
chronic itch following AEW treatment (5 days). *p <
0.05, n = 6 mice per group.
(F–H) Intrathecal or systemic injection of SVmab1
reduces DNFB-induced chronic itch. (F) Paradigm
and time course of DNFB-induced chronic itch.
(G) Intrathecal (50 mg) injection of SVmab1 on day
10 reduces chronic itch. (H) Systemic injection of
SVmab1 (50 mg/kg, i.v.) on day 12 reduces
chronic itch. *p < 0.05, n = 6 mice per group.
(I and J) SVmab1 inhibits chronic itch-enhanced
excitatory synaptic transmission in spinal cord
slices 5 days after AEW treatment. (I) Traces of
spontaneous EPSCs (sEPSCs) in lamina IIo neu-
rons. (Bottom) Enlargements of traces (1, 2, 3)
before and during the CTmab and SVmab1 treat-
ment (300 nM). (J) Frequency of sEPSCs in lamina
IIo neurons. Note that sEPSCs are potentiated in
chronic itch, and this potentiation is inhibited by
SVmab1. *p < 0.05, n = 5 neurons per group.
All of the data are shown as means ± SEM.recombinant NaV1.7 DII VSD were used for screening. Monoclonal antibodies
were scaled up using a hollow fiber bioreactor (Fibercell Systems) and purified
on a protein G agarose column according to the manufacturer’s protocol
(Invitrogen).
Whole-Cell Patch-Clamp Recordings in HEK293 Cells
See Extended Experimental Procedures for a full description. Human NaV1.7
cDNA was a gift from N. Klugbauer, rNaV1.8 cDNA was a gift from J. Wood,
hNaV1.3 cDNA was a gift from A. George, and hNaV1.4 cDNA was a gift
from J. Trimmer. hNaV1.1, rNav1.2, and mNaV1.5 cDNAs were all gifts from
G. Pitt. mNaV1.6 was a gift from Al Goldin. HEK293 cells were transfected
with plasmids containing NaV channel cDNAs, and whole-cell recordings
were performed 24 hr after transfection. b1-subunit cDNA was cotransfected
for NaV1.1 and NaV1.2 recordings. Data were acquired with an Axopatch 200B
amplifier (Axon Instruments). Currents were sampled at a rate of 10 kHz and
filtered at 3 kHz. To record current-voltage relationships, cells were held
at 120 mV and current traces were elicited using 30 ms voltage steps be-
tween 80 and +60 mV with 10 mV increments. The voltage dependence ofCell 157, 1393–14channel activation was calculated by measuring
the peak currents at test potentials ranging from
90 mV to +10 mV evoked in 5 mV increments
from a holding potential of 120 mV. The voltage
dependence of steady-state inactivation was
determined using 500 ms conditioning prepulses
ranging from 110 mV to 30 mV from a holding
potential of –120 mV in 5 mV increments, followed
by a test pulse to –10 mV for 30 ms. The peak INa
was normalized to its respective maximum value
(maxINa) and plotted as a function of the prepulse
potential. State (use)-dependent inhibition of
hNaV1.7 by SVmab1 was determined by mea-
suring current amplitudes during 30 ms depolariz-
ing pulses to 10 mV applied from a holding
potential of 120 mV at 0.1, 2, and 10 Hz in the presence of 100 nM SVmab1.
Data analysis and curve fitting were performed with OrignPro (OriginLab).
Animals
Adult CD1 mice (male, 25–35 g) were used for all of the behavioral studies.
Young mice (4–6 weeks) were used for electrophysiological studies in spinal
cord slices. All of the animal procedures were approved by the Institutional
Animal Care & Use Committee (IACUC) of Duke University.
For behavioral tests, animals were habituated to the environment for at least
2 days before the testing. All of the behaviors were tested blindly. For spinal
intrathecal injection, spinal cord puncture was made with a 30G needle
between the L5 and L6 level to deliver reagents (10 ml) to the cerebral spinal
fluid (Hylden and Wilcox, 1980).
Pain Models and Behavioral Testing of Pain
See Extended Experimental Procedures for a full description. To produce in-
flammatory pain, diluted formalin (5%, 20 ml) was injected into the plantar sur-
face of a hindpaw. To produce neuropathic pain model of chronic constriction04, June 5, 2014 ª2014 Elsevier Inc. 1401
injury (CCI), the sciatic nerve was loosely ligated under isoflurane anesthesia.
We assessed formalin-evoked spontaneous inflammatory pain by measuring
the time (seconds) mice spent on licking or flinching the affected paw every
5 min for 45 min. For testing mechanical sensitivity after nerve injury, we stim-
ulate hindpaws of mice with a series of von Frey hairs (0.02–2.56 g, Stoelting)
and determined the 50%pawwithdrawal threshold. For testingmotor function,
we used a rota-rod system. The speed of rotation was accelerated from 2 to 20
r.p.m. in 3 min, and the falling latency was recorded (Liu et al., 2012).
Itch Models and Behavioral Testing of Itch
See Extended Experimental Procedures for a full description. Mice were
habituated to the testing environment daily for at least two days before anal-
ysis. To elicit acute itch, we injected 50 ml of pruritic agent compound 48/80
(100 mg) or chloroquine (200 mg) intradermally in the nape of the neck or GRP
(1 nmol) intrathecally and counted the number of scratches every 5 min for
30 min after the injection. To induce chronic itch, we painted the neck skin
with acetone and diethyether (1:1) followed by water (AEW) twice a day
for 4 days and examined spontaneous itch by counting the number of
scratches for 60 min on day 5. To determine chronic itch-induced synaptic
plasticity in the lumbar superficial spinal cord, we also painted hindpaw
with AEW. We also generated the allergic contact dermatitis (ACD) model
of chronic itch by applying the hapten 2,4-dinitrofluorobenzene (DNFB) to
the back skin.
Patch-Clamp Recordings in Dissociated DRG Neurons and Whole-
Mount DRG
See Extended Experimental Procedures for a full description. DRGs were
digested with collagenase/dispase II, followed by trypsin, and mechanically
dissociated. DRG cells were grown in a neurobasal-defined medium for
24 hr before use. Whole-cell voltage-clamp and current-clamp recordings
were performed at room temperature to measure currents and action poten-
tials, respectively, using an Axopatch-200B amplifier. The resistance of the
pipettes was 4–5 MU. For whole-mount DRG preparation, DRGs were care-
fully removed and placed in cold oxygenated ACSF and digested with a
mixture of 1.0 mg/ml proteinase and 1.6 mg/ml collagenase for 30 min at
37C. For patch-clamp recordings in whole-mount DRG neurons, the glass
recording pipettes were filled with a Cs+-based internal solution. Transient
sodium current (INaT) was evoked by a 50 ms step depolarization to +0 mV
from the holding potential of 70 mV. Persistent sodium current (INaP) was
recorded by applying a 3 s depolarization ramp current from 80 to
10 mV under a holding potential of 60 mV. The plot was fitted using
the Origin software.
Spinal Cord Slice Preparation and Patch-Clamp Recordings
See Extended Experimental Procedures for a full description. A portion of the
lumbar spinal cord (L4-L5) was removed from mice (4- to 6-weeks-old) under
urethane anesthesia (1.5–2.0 g/kg, i.p.) and kept in preoxygenated ice-cold
Krebs solution. Transverse slices (400–600 mm) were cut on a vibrating micro-
slicer. The slices were perfused with Kreb’s solution (8–10 ml/min) that was
saturated with 95% O2 and 5% CO2 at 36 ± 1
C for at least 1–3 hr prior to
experiment. The whole-cell patch-clamp recordings were made from lamina
IIo neurons in voltage-clamp mode. After establishing the whole-cell configu-
ration, neurons were held at the potential of 70 mV to record sEPSCs (Liu
et al., 2012). Membrane currents were amplified with an Axopatch 200B ampli-
fier (Axon Instruments) in voltage-clamp mode. Signals were filtered at 2 kHz
and digitized at 5 kHz. Data were stored with a personal computer using
pCLAMP 10 software and were analyzed with Mini Analysis (Synaptosoft).
Data Analysis
The differences between the means of the control and treatment values were
determined using an unpaired t test. A value of p < 0.05 was considered to be
statistically significant. All data were expressed as means ± SEM. For electro-
physiology in spinal cord slices, those cells that showed >5% changes from
the baseline levels during drug perfusion were regarded as responding ones.
We collected the baseline recordings for 2 min and the recordings in the first
2 min of drug treatment for statistical analysis using unpaired two-tailed
student’s t test. Behavioral data were analyzed using student’s t test (two1402 Cell 157, 1393–1404, June 5, 2014 ª2014 Elsevier Inc.groups) or one-way ANOVA followed by posthoc Bonferroni test. The criterion
for statistical significance was p < 0.05.
SUPPLEMENTAL INFORMATION
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